BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
Interesting BMRN Put And Call Options For December 20th
Notable Thursday Option Activity: CBRL, BMRN, HNRG
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Despite its growth, NASDAQ:BMRN remains within the realm of affordability.
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of...
BioMarin Pharmaceutical Enters Oversold Territory (BMRN)
Noteworthy Wednesday Option Activity: CAR, BMRN, GOOG
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and...
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host...
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development...
BioMarin Pharmaceutical is Now Oversold (BMRN)
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
The companies could soon face off in the growth treatment market for children with a genetic disorder.
Noteworthy Thursday Option Activity: BMRN, KBR, CPRI